mouse anti human tlr2 cd282 Search Results


fluorescence labeled antibody  (Miltenyi Biotec)
95
Miltenyi Biotec fluorescence labeled antibody
Fluorescence Labeled Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluorescence labeled antibody/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
fluorescence labeled antibody - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
reafinity  (Miltenyi Biotec)
95
Miltenyi Biotec reafinity
Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/reafinity/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
reafinity - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
cd282 tlr2 apc  (Miltenyi Biotec)
95
Miltenyi Biotec cd282 tlr2 apc
Cd282 Tlr2 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd282 tlr2 apc/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd282 tlr2 apc - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
tlr2 pe vio615  (Miltenyi Biotec)
95
Miltenyi Biotec tlr2 pe vio615
Tlr2 Pe Vio615, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tlr2 pe vio615/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
tlr2 pe vio615 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
tlr2 pe vio770  (Miltenyi Biotec)
95
Miltenyi Biotec tlr2 pe vio770
Co-stimulation with TLR1/2, <t>TLR2/6,</t> and TLR5 agonists enhances the proliferative response of human blood-derived CD8 + T cells to TCR triggering. (A) Expression profiles of surface TLRs in resting CD8 + T cells within human blood mononuclear cells (PBMCs). The T cell subpopulations of human PBMCs were identified by staining the cells with antibodies against CD3, CD4, and CD8; the TLR expression was measured by flow cytometry and expressed as the percentage of positively stained cells. Shown is aggregated data of 12 samples. (B and C) Co-stimulatory effects of different TLR agonists on the proliferation of human PBMC-derived CD8 + T cells. CD8+T cells were purified from human PBMCs, stained with eFluor 670, and then stimulated with ant-CD3 beads, anti-CD3/CD28 beads, or anti-CD3 beads coupled with the indicated TLRs agonists. Cells were harvested 7 days later and dilution of eFluor 670 was determined by flow cytometry to measure cellular proliferation, with representative flow cytometry plot and data summary (n = 3) shown in (B) and (C) , respectively. (D,E) Determination of optimal dosages of TLR agonists required for co-stimulation of ex vivo proliferation of human CD8 + T cells. CD8+T cells purified from human PBMCs were stimulated with anti-CD3 beads in presence of various concentration of TLR1/2 agonist, <t>TLR2/6</t> agonist, or TLR5 agonist after labelling with eFluor 670. Flow cytometry analyses were performed on day 4 and 6 after stimulation to determine the cellular proliferation through assessment of eFluor 670 dilution. Shown is aggregated data of 3 samples.
Tlr2 Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tlr2 pe vio770/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
tlr2 pe vio770 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
biotinylated tlr2 antibody  (Miltenyi Biotec)
95
Miltenyi Biotec biotinylated tlr2 antibody
Co-stimulation with TLR1/2, <t>TLR2/6,</t> and TLR5 agonists enhances the proliferative response of human blood-derived CD8 + T cells to TCR triggering. (A) Expression profiles of surface TLRs in resting CD8 + T cells within human blood mononuclear cells (PBMCs). The T cell subpopulations of human PBMCs were identified by staining the cells with antibodies against CD3, CD4, and CD8; the TLR expression was measured by flow cytometry and expressed as the percentage of positively stained cells. Shown is aggregated data of 12 samples. (B and C) Co-stimulatory effects of different TLR agonists on the proliferation of human PBMC-derived CD8 + T cells. CD8+T cells were purified from human PBMCs, stained with eFluor 670, and then stimulated with ant-CD3 beads, anti-CD3/CD28 beads, or anti-CD3 beads coupled with the indicated TLRs agonists. Cells were harvested 7 days later and dilution of eFluor 670 was determined by flow cytometry to measure cellular proliferation, with representative flow cytometry plot and data summary (n = 3) shown in (B) and (C) , respectively. (D,E) Determination of optimal dosages of TLR agonists required for co-stimulation of ex vivo proliferation of human CD8 + T cells. CD8+T cells purified from human PBMCs were stimulated with anti-CD3 beads in presence of various concentration of TLR1/2 agonist, <t>TLR2/6</t> agonist, or TLR5 agonist after labelling with eFluor 670. Flow cytometry analyses were performed on day 4 and 6 after stimulation to determine the cellular proliferation through assessment of eFluor 670 dilution. Shown is aggregated data of 3 samples.
Biotinylated Tlr2 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated tlr2 antibody/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
biotinylated tlr2 antibody - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

Image Search Results


Co-stimulation with TLR1/2, TLR2/6, and TLR5 agonists enhances the proliferative response of human blood-derived CD8 + T cells to TCR triggering. (A) Expression profiles of surface TLRs in resting CD8 + T cells within human blood mononuclear cells (PBMCs). The T cell subpopulations of human PBMCs were identified by staining the cells with antibodies against CD3, CD4, and CD8; the TLR expression was measured by flow cytometry and expressed as the percentage of positively stained cells. Shown is aggregated data of 12 samples. (B and C) Co-stimulatory effects of different TLR agonists on the proliferation of human PBMC-derived CD8 + T cells. CD8+T cells were purified from human PBMCs, stained with eFluor 670, and then stimulated with ant-CD3 beads, anti-CD3/CD28 beads, or anti-CD3 beads coupled with the indicated TLRs agonists. Cells were harvested 7 days later and dilution of eFluor 670 was determined by flow cytometry to measure cellular proliferation, with representative flow cytometry plot and data summary (n = 3) shown in (B) and (C) , respectively. (D,E) Determination of optimal dosages of TLR agonists required for co-stimulation of ex vivo proliferation of human CD8 + T cells. CD8+T cells purified from human PBMCs were stimulated with anti-CD3 beads in presence of various concentration of TLR1/2 agonist, TLR2/6 agonist, or TLR5 agonist after labelling with eFluor 670. Flow cytometry analyses were performed on day 4 and 6 after stimulation to determine the cellular proliferation through assessment of eFluor 670 dilution. Shown is aggregated data of 3 samples.

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Improving the ex vivo expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors

doi: 10.3389/fbioe.2022.1027619

Figure Lengend Snippet: Co-stimulation with TLR1/2, TLR2/6, and TLR5 agonists enhances the proliferative response of human blood-derived CD8 + T cells to TCR triggering. (A) Expression profiles of surface TLRs in resting CD8 + T cells within human blood mononuclear cells (PBMCs). The T cell subpopulations of human PBMCs were identified by staining the cells with antibodies against CD3, CD4, and CD8; the TLR expression was measured by flow cytometry and expressed as the percentage of positively stained cells. Shown is aggregated data of 12 samples. (B and C) Co-stimulatory effects of different TLR agonists on the proliferation of human PBMC-derived CD8 + T cells. CD8+T cells were purified from human PBMCs, stained with eFluor 670, and then stimulated with ant-CD3 beads, anti-CD3/CD28 beads, or anti-CD3 beads coupled with the indicated TLRs agonists. Cells were harvested 7 days later and dilution of eFluor 670 was determined by flow cytometry to measure cellular proliferation, with representative flow cytometry plot and data summary (n = 3) shown in (B) and (C) , respectively. (D,E) Determination of optimal dosages of TLR agonists required for co-stimulation of ex vivo proliferation of human CD8 + T cells. CD8+T cells purified from human PBMCs were stimulated with anti-CD3 beads in presence of various concentration of TLR1/2 agonist, TLR2/6 agonist, or TLR5 agonist after labelling with eFluor 670. Flow cytometry analyses were performed on day 4 and 6 after stimulation to determine the cellular proliferation through assessment of eFluor 670 dilution. Shown is aggregated data of 3 samples.

Article Snippet: For surface staining, cells were stained in FACS buffer (PBS supplemented with 2% bovine serum albumin) sequentially with a fixable viability dye and a combination of the following antibodies: CD3-ECD (IM2705U, Beckman coulter), CD8-BV711(563677, BD Pharmingen), CD4-percp-cy5.5 (300530, Biolegend), CD14-BV786(563699, BD Pharmingen), TLR1-FITC(sc-47709FITC, Santa Cruz), TLR2-PE-Vio770 (130-099-021, Miltenyi), TLR4-BV421 (312811, Biolegend), TLR5-Alexa Fluor 700 (NBP2-24787AF700, NOVUS biology), TLR6-DyLight 350 (NB100-56536UV, NOVUS biology), CD3-BV421(562426, BD Pharmingen), CD8-APC-H7(580179, BD Pharmingen), PD-1-PE-CF594(565024, BD Pharmingen), CTLA-4-APC(555855, BD Pharmingen), ICOS-FITC(313505, Biolegend), 4-1BB-PE-Cy7 (309818, Biolegend).

Techniques: Derivative Assay, Expressing, Staining, Flow Cytometry, Purification, Ex Vivo, Concentration Assay

Co-stimulation with a combination of TLR1/2, TLR2/6, and TLR5 agonists enhances the transcriptional induction of proliferative-related genes in human blood-derived CD8 + T cells responding to TCR triggering. CD8+T cells purified from human PBMCs were stimulated with anti-CD3 beads in the presence or absence of a combination of TLR1/2 agonist, TLR2/6 agonist, and TLR5 agonist. Cells were harvested 24 h later for extracting total RNA, which was subjected to RNA sequencing. The differentially expressed genes showing >2-fold change between minus and plus TLR agonists groups were clustered based on Gene Ontology (GO) enrichment analysis (A) . Shown in (B) is the heatmap of representative proliferation-related genes that were identified to be co-stimulated by TLR agonists. H1 to H3 represent samples from three healthy individuals.

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Improving the ex vivo expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors

doi: 10.3389/fbioe.2022.1027619

Figure Lengend Snippet: Co-stimulation with a combination of TLR1/2, TLR2/6, and TLR5 agonists enhances the transcriptional induction of proliferative-related genes in human blood-derived CD8 + T cells responding to TCR triggering. CD8+T cells purified from human PBMCs were stimulated with anti-CD3 beads in the presence or absence of a combination of TLR1/2 agonist, TLR2/6 agonist, and TLR5 agonist. Cells were harvested 24 h later for extracting total RNA, which was subjected to RNA sequencing. The differentially expressed genes showing >2-fold change between minus and plus TLR agonists groups were clustered based on Gene Ontology (GO) enrichment analysis (A) . Shown in (B) is the heatmap of representative proliferation-related genes that were identified to be co-stimulated by TLR agonists. H1 to H3 represent samples from three healthy individuals.

Article Snippet: For surface staining, cells were stained in FACS buffer (PBS supplemented with 2% bovine serum albumin) sequentially with a fixable viability dye and a combination of the following antibodies: CD3-ECD (IM2705U, Beckman coulter), CD8-BV711(563677, BD Pharmingen), CD4-percp-cy5.5 (300530, Biolegend), CD14-BV786(563699, BD Pharmingen), TLR1-FITC(sc-47709FITC, Santa Cruz), TLR2-PE-Vio770 (130-099-021, Miltenyi), TLR4-BV421 (312811, Biolegend), TLR5-Alexa Fluor 700 (NBP2-24787AF700, NOVUS biology), TLR6-DyLight 350 (NB100-56536UV, NOVUS biology), CD3-BV421(562426, BD Pharmingen), CD8-APC-H7(580179, BD Pharmingen), PD-1-PE-CF594(565024, BD Pharmingen), CTLA-4-APC(555855, BD Pharmingen), ICOS-FITC(313505, Biolegend), 4-1BB-PE-Cy7 (309818, Biolegend).

Techniques: Derivative Assay, Purification, RNA Sequencing

TLR agonists is an advantageous supplement benefiting the ex vivo expansion of human blood-derived PD1+ CD8 + T cells. (A) Exploration of optimal combination of TLR agonists in facilitating the ex vivo expansion of human blood-derived PD1+ CD8 + T cells. PD1+ CD8 + T cells isolated from blood samples of health individuals were continuously cultured for 21 days in medium containing anti-CD3/anti-CD28 beads and IL-7/IL-15, either alone or in the presence of different combination of TLR1/2, TLR2/6, and TLR5 agonists. Cell counting was performed at various time points throughout the culture period to generate the cell expansion curve. (B) Expansion curves of PD1+ CD8 + T cells derived from blood samples of cancer patients with different tumor types. Among the total of fifteen samples, seven were with lung cancer, four with pancreatic cancer, and the rest four with other types of cancers. Five samples from healthy individuals were also included as controls.

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Improving the ex vivo expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors

doi: 10.3389/fbioe.2022.1027619

Figure Lengend Snippet: TLR agonists is an advantageous supplement benefiting the ex vivo expansion of human blood-derived PD1+ CD8 + T cells. (A) Exploration of optimal combination of TLR agonists in facilitating the ex vivo expansion of human blood-derived PD1+ CD8 + T cells. PD1+ CD8 + T cells isolated from blood samples of health individuals were continuously cultured for 21 days in medium containing anti-CD3/anti-CD28 beads and IL-7/IL-15, either alone or in the presence of different combination of TLR1/2, TLR2/6, and TLR5 agonists. Cell counting was performed at various time points throughout the culture period to generate the cell expansion curve. (B) Expansion curves of PD1+ CD8 + T cells derived from blood samples of cancer patients with different tumor types. Among the total of fifteen samples, seven were with lung cancer, four with pancreatic cancer, and the rest four with other types of cancers. Five samples from healthy individuals were also included as controls.

Article Snippet: For surface staining, cells were stained in FACS buffer (PBS supplemented with 2% bovine serum albumin) sequentially with a fixable viability dye and a combination of the following antibodies: CD3-ECD (IM2705U, Beckman coulter), CD8-BV711(563677, BD Pharmingen), CD4-percp-cy5.5 (300530, Biolegend), CD14-BV786(563699, BD Pharmingen), TLR1-FITC(sc-47709FITC, Santa Cruz), TLR2-PE-Vio770 (130-099-021, Miltenyi), TLR4-BV421 (312811, Biolegend), TLR5-Alexa Fluor 700 (NBP2-24787AF700, NOVUS biology), TLR6-DyLight 350 (NB100-56536UV, NOVUS biology), CD3-BV421(562426, BD Pharmingen), CD8-APC-H7(580179, BD Pharmingen), PD-1-PE-CF594(565024, BD Pharmingen), CTLA-4-APC(555855, BD Pharmingen), ICOS-FITC(313505, Biolegend), 4-1BB-PE-Cy7 (309818, Biolegend).

Techniques: Ex Vivo, Derivative Assay, Isolation, Cell Culture, Cell Counting